First-pass extracted concept

vein graft intimal hyperplasia

Candidate: concept label1 source documents4 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

IH, postoperative intimal hyperplasia

Evidence Snippets

its long-term patency is limited by postoperative intimal hyperplasia (IH) and accelerated atherosclerosis.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 4 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1design needsupports2025Source 1DOI PubMed

The complexity of vascular smooth muscle cell regulatory networks and the limitations of current interventions support a need for integrative approaches combining molecular targeting with innovative delivery systems.

Claim 2mechanistic rolesupports2025Source 1DOI PubMed

Vascular smooth muscle cell phenotypic switching is a central mechanism in vein graft intimal hyperplasia.

Claim 3pathway regulationsupports2025Source 1DOI PubMed

PDGF-BB, TGF-β, MAPK, mTOR, NF-κB, and non-coding RNAs are described as key regulators of vascular smooth muscle cell phenotypic switching in vein graft intimal hyperplasia.

Claim 4therapeutic strategysupports2025Source 1DOI PubMed

Emerging strategies to mitigate vein graft intimal hyperplasia include optimized surgical harvesting techniques, improved conduit preservation solutions, pharmacological agents, gene therapy, and venous external stenting.